A Randomized, Double-Blind, Double-Dummy, Positive-Controlled, Crossover Study to Determine Electrocardiographic Effects of BMS-955176 in Healthy Subjects

Trial Profile

A Randomized, Double-Blind, Double-Dummy, Positive-Controlled, Crossover Study to Determine Electrocardiographic Effects of BMS-955176 in Healthy Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs GSK 3532795 (Primary) ; Moxifloxacin
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb; ViiV Healthcare
  • Most Recent Events

    • 29 Mar 2017 This study was terminated early due to neuropsychiatric serious adverse events reported by 2 participants.
    • 06 Mar 2017 Status changed to discontinued.
    • 09 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Aug 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top